Bruker Corporation research snapshot
BRKR AI stock analysis reads Bruker as a specialized scientific instruments company with leading positions in magnetic resonance, mass spectrometry, microscopy, spatial biology, semiconductor metrology, and superconducting technologies. Q1 2026 revenue rose 2.7% to $823.4 million, BSI bookings grew at a high single digit rate organically, and the BSI book-to-bill ratio stayed above 1.0x for a third consecutive quarter. Bruker reaffirmed FY2026 guidance of $3.57 billion to $3.60 billion in revenue and $2.10 to $2.15 in non-GAAP EPS, and management expects a return to organic growth in Q2. At the July 31, 2026 close near $62.84, the BRKR AI stock forecast is a scenario exercise rather than a fixed price prediction. This page is for informational use only and is not investment advice.
Current price
$62.84 at the July 31, 2026 close
Market cap
$9.57 billion calculated from 152.23 million shares, versus about $9.57 billion reported
AI score
62 / 100
Rating
Scientific instruments franchise with a recovery under way, but valuation is demanding and execution risk remains
Trend status
Above the 20-day, 50-day, and 200-day moving averages with positive but not overbought momentum
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Bruker sells complex research and analytical instruments used in life science, materials, semiconductor, industrial, and security applications, with an expanding diagnostics portfolio. | High |
| Moat | Technology depth, installed workflows, application expertise, brand, service, and customer switching friction support the moat, although some diagnostics and microscopy categories face strong competition. | Medium-high |
| Management | Frank H. Laukien has led Bruker since February 1991 and is its largest stockholder, aligning long-term ownership with the business while increasing key-person and governance concentration risk. | High |
| Financial trend | Q1 2026 revenue rose 2.7% to $823.4 million with free cash flow of $47.0 million, and BSI book-to-bill stayed above 1.0x, but GAAP earnings remain weak and TTM free cash flow is still thin. | High |
| Valuation | At $62.84, BRKR trades at about 28x forward earnings, 2.77x sales, and 3.91x book value, with a forward PE above the level implied when the stock was lower in mid-2026. | High |
| Technical trend | The stock is above the 20-day average near $60.16, 50-day average near $57.56, and 200-day average near $45.78, with RSI near 57.6, and it is approaching the $65.30 52-week high. | Medium |
| Risk level | The largest risks are weaker US academic and government funding, China and tariff pressure, acquisition integration, debt service, impairment, foreign exchange, and key-person concentration. | High |
| AI confidence | Descriptive data confidence is high because company filings and independent market data align. Return confidence is lower because normalized earnings and cash conversion are still being rebuilt. | High data confidence |
| Investment certainty | The business is understandable and technically differentiated, and orders are improving, but the current price already reflects a recovery that must be delivered through the rest of 2026. | Medium |
BRKR AI stock forecast
The BRKR AI stock forecast uses the FY2026 non-GAAP EPS guidance midpoint of $2.125 as a normalized starting point. A three-year model using 15%, 8%, and negative 5% annual EPS growth with 32x, 27x, and 22x exit multiples produced mechanical values of about $103.4, $72.3, and $40.1. These are scenario outputs, not guaranteed targets, and they exclude dividends and future dilution.
$98 to $108
More likely if BSI bookings convert into organic growth, AI-related semiconductor metrology demand stays strong, US academic funding releases in late 2026, acquisitions add earnings without balance-sheet strain, and margins move toward the 20% operating target.
$68 to $76
More likely if FY2026 guidance is achieved, organic growth returns in Q2 as management expects, non-GAAP EPS grows near high single digits to low double digits over three years, and the market holds a high-twenties earnings multiple on the recovery case.
$37 to $43
More likely if US academic and government budgets stay frozen, China and tariff pressure deepen, acquisitions underperform, free cash flow stays near 2025 levels, or the market reduces the multiple toward the low twenties.
BRKR AI technical analysis
BRKR AI technical analysis is constructive as of the July 31, 2026 close. The price is above the 20-day, 50-day, and 200-day moving averages, and StockAnalysis reports RSI near 57.6. The stock has gained 53.66% over 52 weeks and is testing the $65.30 52-week high, so momentum is positive but a break-and-hold above that level needs volume and Q2 earnings confirmation.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $62.84 | StockAnalysis and MarketBeat reported the regular-market close on July 31, 2026. |
| Immediate support | $60.05 to $61.74 | The July 27 through July 31 closing range forms the first short-term demand zone. |
| Secondary support | $58.20 to $59.90 | Mid-July closes clustered in this area before the latest push higher. |
| Near resistance | $64.30 to $65.30 | The July 30 high near $64.43 and the July 31 intraday high near $65.30 define the current test. |
| Major resistance | $65.30 | The July 31 high is the 52-week high and the main supply zone to watch. |
| Moving averages | 20-day $60.16, 50-day $57.56, 200-day $45.78 | The 20-day figure is calculated from StockAnalysis daily closes. The 50-day and 200-day figures are from its August 2026 statistics snapshot. |
| Momentum | RSI 57.62, positive but not overbought | The RSI reading is near the upper half of the neutral range. A move above resistance needs volume and Q2 earnings confirmation. |
| Volume and volatility | 1.89M average shares, beta 1.27, 52-week change +53.66% | StockAnalysis statistics as checked on August 2, 2026. Price volatility is higher than the broad market reference. |
| Invalidation | Daily close below $57.56 | A sustained break below the 50-day average would weaken the current recovery setup and require a new fundamental review. |
BRKR AI trading strategy
The BRKR AI trading strategy below is a rules-based research framework, not personal advice. It combines price confirmation with bookings, organic revenue, academic funding, semiconductor demand, cash conversion, leverage, and acquisition execution.
Watch for BRKR to hold above the $64.30 to $65.30 area on rising volume while Q2 results confirm the return to organic growth, BSI book-to-bill stays above 1.0x, and non-GAAP operating margin improves toward 12% or higher.
A failed breakout followed by a close below $60.05 reduces short-term confidence. A close below $57.56 invalidates the medium-term trend setup.
If BRKR pulls back toward $60.05 to $61.74 without a guidance cut, compare the price move with bookings, US academic funding, China demand, currency effects, and the progress of cost savings.
Do not average down solely because the stock is below a recent high. Avoid treating a low price-to-sales ratio as protection if free cash flow and operating margins continue to deteriorate.
Track BSI bookings and book-to-bill, organic revenue, gross and operating margin, FY2026 EPS guidance, free cash flow, cash and debt, acquisition contribution, impairment charges, insider ownership, US academic funding, and China exposure.
Position sizing should reflect integration risk, debt service, currency swings, public research funding, tariff changes, product acceptance, and concentrated ownership.
Investment research summary
Bruker sells high-performance scientific instruments and analytical and diagnostic solutions. Customers pay for measurement accuracy, reliability, application support, workflow compatibility, and the ability to answer difficult questions in biology, chemistry, materials, semiconductors, and infectious disease detection.
The moat is strongest in technical know-how, proprietary instrument design, installed workflows, application libraries, service relationships, and a global specialist sales network. Switching costs rise when laboratories validate methods, train staff, and build datasets around a platform. Network effects are limited, so the moat must be renewed through product development and customer success.
The thesis fails if US academic and government budgets stay frozen, industrial customers delay capital spending, China and tariff pressures reduce demand, acquisitions require more restructuring, impairment charges recur, debt service absorbs cash, or new products fail to gain adoption. The 2025 organic decline and thin free cash flow show that a high-quality product portfolio does not remove cycle risk.
Frank H. Laukien has served as Bruker chairman, president, and CEO since February 1991 and is the largest stockholder. Long tenure and meaningful ownership can support patient investment, but they also create key-person and governance concentration risk. Management has taken out more than $140 million of cost savings, guided to meaningful operating margin expansion in 2026 and 2027, and expects double-digit EPS growth for multiple years.
Bruker participates in durable trends including structural biology, multiomics, spatial biology, advanced materials, semiconductor process control, and infection diagnostics. Semiconductor metrology demand tied to AI fab expansion is a notable growth driver, but revenue timing depends on government grants, pharmaceutical research budgets, semiconductor capital spending, currency, geopolitics, and customer financing.
At about 28x forward earnings, 2.77x sales, and 3.91x book value, BRKR is priced for a successful recovery. TTM net income is negative and free cash flow per share is about $0.34, so the margin of safety depends on guidance delivery, operating-margin recovery, better cash conversion, and disciplined acquisition spending.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BRKR closing price | $62.84 on July 31, 2026 | StockAnalysis and MarketBeat | August 2, 2026 |
| Shares outstanding | 152.23 million current shares, up 0.63% year over year; 152.2 million basic weighted shares in Q1 2026 | StockAnalysis statistics and Bruker Q1 2026 Financial Results | August 2, 2026 |
| Market capitalization verification | $9.57 billion from $62.84 x 152.23 million shares; 0.04% deviation from reported $9.57 billion | Pineify financial_rigor.py and StockAnalysis statistics | August 2, 2026 |
| Q1 2026 operating results | $823.4 million revenue, up 2.7% year over year, down 4.4% organically, with GAAP EPS of $0.02 and non-GAAP EPS of $0.31 | Bruker Q1 2026 Financial Results | August 2, 2026 |
| Q1 2026 bookings and book-to-bill | BSI bookings up high single digits organically year over year; BSI book-to-bill above 1.0x for a third consecutive quarter | Bruker Q1 2026 Financial Results | August 2, 2026 |
| FY2026 guidance | $3.57 billion to $3.60 billion revenue and $2.10 to $2.15 non-GAAP EPS, reconfirmed in Q1 2026 | Bruker Q1 2026 Financial Results | August 2, 2026 |
| FY2025 revenue and free cash flow | Revenue of $3.437 billion (up 2.1%) and free cash flow of $43.3 million, consistent across the annual report, StockAnalysis, and Macrotrends | Bruker 2025 Annual Report, StockAnalysis, and Macrotrends | August 2, 2026 |
| TTM financials to March 2026 | Revenue of $3.459 billion, net loss of $36.4 million, and free cash flow of $51.3 million | StockAnalysis financials | August 2, 2026 |
| Cash and debt | $133.4 million cash and about $1.71 billion debt at March 31, 2026, including $1,662.9 million long-term debt | Bruker Q1 2026 Financial Results and StockAnalysis statistics | August 2, 2026 |
| Technical snapshot | 50-day average $57.56, 200-day average $45.78, RSI 57.62, average volume 1.89 million, beta 1.27, 52-week change +53.66% | StockAnalysis statistics | August 2, 2026 |
| Analyst consensus | Buy rating from 13 analysts with a 12-month price target of $59.75, about 4.9% below the latest close | StockAnalysis forecast | August 2, 2026 |
| Recent company events | Acquired the DISQVER clinical metagenomics platform from Noscendo GmbH on July 15, 2026; Q2 2026 results scheduled for August 4, 2026 | Business Wire and Bruker press releases | August 2, 2026 |
This BRKR AI stock analysis is an informational research tool only and is not investment advice, a recommendation, or a solicitation to buy or sell securities. Forecast scenarios are based on available public data as of August 3, 2026 and can be wrong if earnings, research budgets, tariffs, currency, acquisition execution, or market sentiment change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
